Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.60 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7943502 | 0.93 | BACE1 (0.60) | BACE1PRKCITMEM97SIGMAR1BACE2 | |
| SCHEMBL7935754 | 0.89 | BACE1 (0.50) | BACE1PRKCIBACE2 | |
| SCHEMBL7942788 | 0.89 | BACE1 (0.65) | BACE1PRKCITMEM97SIGMAR1BACE2 | |
| SCHEMBL7940764 | 0.88 | BACE1 (0.78) | BACE1 | |
| SCHEMBL7940587 | 0.88 | BACE1 (0.77) | BACE1PRKCIBACE2 | |
| SCHEMBL7941611 | 0.87 | BACE1 (0.65) | BACE1TMEM97SIGMAR1BACE2CYP2D6 | |
| SCHEMBL7945144 | 0.87 | BACE1 (0.67) | BACE1PRKCITMEM97SIGMAR1BACE2 | |
| SCHEMBL7943510 | 0.87 | BACE1 (0.78) | BACE1PRKCITMEM97SIGMAR1 | |
| SCHEMBL7934099 | 0.86 | BACE1 (0.66) | BACE1PRKCITMEM97SIGMAR1BACE2 | |
| SCHEMBL7941641 | 0.86 | BACE1 (0.62) | BACE1PRKCITMEM97SIGMAR1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2360155-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | Shionogi & Co., Ltd. (JP) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010047372-A1 | 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY | 塩野義製薬株式会社 (JP) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237576-A1 | 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY | BACE1, APP, BACE2 | BACE1 1/4885PRKCI 2747/4885TMEM97 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.